Full Press Release Details
Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited expressed in thousands of Canadian dollars)
Condensed Consolidated Interim Statements of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
| As at | Note | September 30, 2025 | December 31, 2024 | ||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | 240,581 | 218,359 | |||||
| Restricted cash | 19,798 | 19,815 | |||||
| Marketable securities | 139 | 139 | |||||
| Accounts receivable | 26,299 | 28,118 | |||||
| Biological assets | 5 | 3,507 | 1,187 | ||||
| Inventory | 6 | 125,334 | 127,919 | ||||
| Prepaid expenses and deposits | 12,580 | 16,860 | |||||
| Investments | 12 | 595 | 27,560 | ||||
| Assets held for sale | 7 | 746 | 19,051 | ||||
| Net investment in subleases | 10 | 2,754 | 2,832 | ||||
| 432,333 | 461,840 | ||||||
| Non-current assets | |||||||
| Long-term deposits and receivables | 4,460 | 3,679 | |||||
| Right of use assets | 8 | 122,701 | 115,435 | ||||
| Property, plant and equipment | 9 | 152,510 | 145,810 | ||||
| Net investment in subleases | 10 | 12,350 | 15,354 | ||||
| Intangible assets | 11 | 59,224 | 61,325 | ||||
| Investments | 12 | 19,089 | 8,427 | ||||
| Equity-accounted investees | 13 | 391,146 | 413,124 | ||||
| Goodwill | 124,248 | 124,248 | |||||
| Total assets | 1,318,061 | 1,349,242 | |||||
| Liabilities | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | 50,652 | 56,275 | |||||
| Lease liabilities | 15 | 35,158 | 34,256 | ||||
| Derivative warrants | 14 | 26 | |||||
| 85,810 | 90,557 | ||||||
| Non-current liabilities | |||||||
| Lease liabilities | 15 | 119,971 | 118,017 | ||||
| Other liabilities | 12,989 | 7,312 | |||||
| Total liabilities | 218,770 | 215,886 | |||||
| Shareholders' equity | |||||||
| Share capital | 16(b) | 2,295,625 | 2,346,728 | ||||
| Warrants | 667 | 667 | |||||
| Contributed surplus | 66,435 | 57,156 | |||||
| Accumulated deficit | (1,312,710 | ) | (1,323,965 | ) | |||
| Accumulated other comprehensive income ( AOCI ) | 49,274 | 52,770 | |||||
| Total shareholders' equity | 1,099,291 | 1,133,356 | |||||
| Total liabilities and shareholders' equity | 1,318,061 | 1,349,242 |
Commitments and contingencies (note 25)
Subsequent events (note 26)
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
| Three months ended September 30 | Nine months ended September 30 | |||||||||||||||||
| Note | 2025 | 2024 | 2025 | 2024 | ||||||||||||||
| Net revenue | 18 | 244,219 | 236,892 | 693,902 | 662,769 | |||||||||||||
| Cost of sales | 6 | 180,042 | 173,924 | 505,483 | 491,237 | |||||||||||||
| Gross profit | 64,177 | 62,968 | 188,419 | 171,532 | ||||||||||||||
| Investment income | 19 | 1,777 | 5,577 | 6,162 | 12,817 | |||||||||||||
| Share of (loss) profit of equity-accounted investees | 13 | (234 | ) | (13,401 | ) | (4,387 | ) | 999 | ||||||||||
| General and administrative | 45,967 | 49,980 | 137,702 | 142,711 | ||||||||||||||
| Sales and marketing | 3,617 | 2,813 | 10,768 | 8,850 | ||||||||||||||
| Depreciation and amortization | 8,9,11 | 12,928 | 13,389 | 39,076 | 41,051 | |||||||||||||
| Share-based compensation | 17 | 10,883 | 5,702 | 15,190 | 15,428 | |||||||||||||
| Restructuring costs | 1,134 | 1,918 | 2,287 | 2,050 | ||||||||||||||
| Asset impairment (recovery), net | 8,9 | 2,051 | (258 | ) | 2,971 | 2,317 | ||||||||||||
| Research and development | 156 | 76 | 354 | 222 | ||||||||||||||
| Loss (gain) on disposition of assets | 34 | 35 | (54 | ) | 441 | |||||||||||||
| Operating loss | (11,050 | ) | (18,511 | ) | (18,100 | ) | (27,722 | ) | ||||||||||
| Other (expenses) income, net | 20 | (2,269 | ) | 609 | (7,041 | ) | (4,080 | ) | ||||||||||
| Loss before income tax | (13,319 | ) | (17,902 | ) | (25,141 | ) | (31,802 | ) | ||||||||||
| Income tax (expense) recovery | (1,434 | ) | 2,847 | |||||||||||||||
| Net loss | (13,319 | ) | (19,336 | ) | (25,141 | ) | (28,955 | ) | ||||||||||
| Equity-accounted investees - share of other comprehensive income (loss) | 13 | 7,709 | (4,802 | ) | (13,250 | ) | 9,532 | |||||||||||
| Investments at fair value through other comprehensive income ( FVOCI ) - change in fair value | 12 | 12,940 | 9,754 | |||||||||||||||
| Comprehensive income (loss) | 7,330 | (24,138 | ) | (28,637 | ) | (19,423 | ) | |||||||||||
| Net loss attributable to: | ||||||||||||||||||
| Owners of the Company | (13,319 | ) | (19,328 | ) | (25,141 | ) | (27,654 | ) | ||||||||||
| Non-controlling interest | (8 | ) | (1,301 | ) | ||||||||||||||
| (13,319 | ) | (19,336 | ) | (25,141 | ) | (28,955 | ) | |||||||||||
| Comprehensive income (loss) attributable to: | ||||||||||||||||||
| Owners of the Company | 7,330 | (24,130 | ) | (28,637 | ) | (18,122 | ) | |||||||||||
| Non-controlling interest | (8 | ) | (1,301 | ) | ||||||||||||||
| 7,330 | (24,138 | ) | (28,637 | ) | (19,423 | ) | ||||||||||||
| Net loss per common share attributable to owners of the Company | ||||||||||||||||||
| Basic and diluted | 22 | $ | (0.05 | ) | $ | (0.07 | ) | $ | (0.10 | ) | $ | (0.10 | ) |
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
| Note | Share capital | Warrants | Contributed surplus | Contingent consideration | Accumulated deficit | AOCI - Equity-accounted investees | AOCI - Investments at FVOCI | Non- controlling interest | Total | |||||||||||||||||||
| Balance at December 31, 2024 | 2,346,728 | 667 | 57,156 | (1,323,965 | ) | 50,906 | 1,864 | 1,133,356 | ||||||||||||||||||||
| Net loss | (25,141 | ) | (25,141 | ) | ||||||||||||||||||||||||
| Other comprehensive loss (income) | (13,250 | ) | 9,754 | (3,496 | ) | |||||||||||||||||||||||
| Share repurchases | (51,465 | ) | 36,396 | (15,069 | ) | |||||||||||||||||||||||
| Share-based compensation | 17 | 9,641 | 9,641 | |||||||||||||||||||||||||
| Employee awards exercised | 362 | (362 | ) | |||||||||||||||||||||||||
| Balance at September 30, 2025 | 2,295,625 | 667 | 66,435 | (1,312,710 | ) | 37,656 | 11,618 | 1,099,291 |
| Balance at December 31, 2023 | 2,375,950 | 2,260 | 73,014 | 2,279 | (1,260,851 | ) | 19,417 | 17,271 | 1,229,340 | |||||||||||||||||||
| Net loss | (27,654 | ) | (1,301 | ) | (28,955 | ) | ||||||||||||||||||||||
| Other comprehensive income | 9,532 | 9,532 | ||||||||||||||||||||||||||
| Share issuances | 164 | 164 | ||||||||||||||||||||||||||
| Share issuance costs | (57 | ) | (57 | ) | ||||||||||||||||||||||||
| Share issuances by subsidiaries | 52 | 76 | 128 | |||||||||||||||||||||||||
| Acquisition | 3,693 | 3,693 | ||||||||||||||||||||||||||
| Warrants expired | (1,593 | ) | 753 | (840 | ) | |||||||||||||||||||||||
| Share-based compensation | 17 | 11,255 | 11,255 | |||||||||||||||||||||||||
| Employee awards exercised | 3,483 | (3,483 | ) | |||||||||||||||||||||||||
| Distribution declared by subsidiaries | 13 | 13 | ||||||||||||||||||||||||||
| Balance at September 30, 2024 | 2,383,233 | 667 | 81,591 | 2,279 | (1,288,505 | ) | 28,949 | 16,059 | 1,224,273 |
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
| Three months ended September 30 | Nine months ended September 30 | |||||||||||||||||
| Note | 2025 | 2024 | 2025 | 2024 | ||||||||||||||
| Cash provided by (used in): | ||||||||||||||||||
| Operating activities | ||||||||||||||||||
| Net loss for the period | (13,319 | ) | (19,336 | ) | (25,141 | ) | (28,955 | ) | ||||||||||
| Adjustments for: | ||||||||||||||||||
| Income tax expense (recovery) | 1,434 | (2,847 | ) | |||||||||||||||
| Interest and fee income | 19 | (1,675 | ) | (5,577 | ) | (5,849 | ) | (12,886 | ) | |||||||||
| Change in fair value of biological assets | 5 | (784 | ) | 167 | (2,559 | ) | (401 | ) | ||||||||||
| Change in fair value of inventory sold | 1,313 | 1,313 | ||||||||||||||||
| Share-based compensation | 17 | 10,883 | 5,702 | 15,190 | 15,428 | |||||||||||||
| Depreciation and amortization | 8,9,11 | 13,972 | 13,970 | 42,108 | 42,679 | |||||||||||||
| Loss (gain) on disposition of assets | 34 | 35 | (54 | ) | 441 | |||||||||||||
| Inventory impairment and obsolescence | 6 | 1,833 | 413 | 2,663 | 3,395 | |||||||||||||
| Finance costs, net | 20 | 1,812 | 1,740 | 5,149 | 5,522 | |||||||||||||
| Change in estimate of fair value of derivative warrants | (1 | ) | (3,848 | ) | (26 | ) | (4,348 | ) | ||||||||||
| Unrealized foreign exchange (gain) loss | (153 | ) | 80 | 40 | 235 | |||||||||||||
| Transaction costs | 164 | |||||||||||||||||
| Asset impairment (recovery), net | 8,9 | 2,051 | (258 | ) | 2,971 | 2,317 | ||||||||||||
| Share of loss (profit) of equity-accounted investees | 13 | 234 | 13,401 | 4,387 | (999 | ) | ||||||||||||
| Unrealized (gain) loss on marketable securities | 19 | (102 | ) | (313 | ) | 69 | ||||||||||||
| Additions to marketable securities | (327 | ) | 313 | (327 | ) | |||||||||||||
| Income distributions from equity-accounted investees | 10,715 | 68 | 10,715 | |||||||||||||||
| Interest received | 1,409 | 4,496 | 5,628 | 10,317 | ||||||||||||||
| Change in non-cash working capital | 21 | 14,194 | (13 | ) | (282 | ) | (9,722 | ) | ||||||||||
| Net cash provided by operating activities | 31,701 | 22,794 | 45,606 | 30,797 | ||||||||||||||
| Investing activities | ||||||||||||||||||
| Additions to property, plant and equipment | 9 | (5,185 | ) | (1,706 | ) | (8,853 | ) | (5,306 | ) | |||||||||
| Additions to intangible assets | 11 | (2,421 | ) | (2,421 | ) | |||||||||||||
| Additions to investments | 12 | (29,066 | ) | (16,414 | ) | (29,966 | ) | |||||||||||
| Principal payments from investments | 12 | 129 | 10,114 | 27,293 | 12,382 | |||||||||||||
| Proceeds from disposal of investments | 12 | 15,058 | 15,058 | |||||||||||||||
| Capital refunds from equity-accounted investees | 13 | 168 | ||||||||||||||||
| Capital distributions from equity-accounted investees | 13 | 481 | 89,758 | 4,273 | 89,758 | |||||||||||||
| Proceeds from disposal of property, plant and equipment | 166 | 126 | ||||||||||||||||
| Acquisitions, net of cash acquired | 26 | (1,000 | ) | (1,654 | ) | |||||||||||||
| Change in non-cash working capital | 21 | 39 | (191 | ) | 10 | 379 | ||||||||||||
| Net cash provided by investing activities | 10,522 | 66,488 | 20,533 | 63,466 | ||||||||||||||
| Financing activities | ||||||||||||||||||
| Change in restricted cash | (243 | ) | (324 | ) | ||||||||||||||
| Payments on lease liabilities, net | 10,15 | (9,920 | ) | (9,780 | ) | (29,217 | ) | (27,002 | ) | |||||||||
| Repurchase of common shares | 16(b) | (3 | ) | (15,034 | ) | |||||||||||||
| Proceeds from issuance of shares, net of costs | (57 | ) | ||||||||||||||||
| Issuance of common shares by subsidiaries | 174 | |||||||||||||||||
| Change in non-cash working capital | 21 | 57 | 783 | 334 | 881 | |||||||||||||
| Net cash used in financing activities | (9,866 | ) | (9,240 | ) | (43,917 | ) | (26,328 | ) | ||||||||||
| Change in cash and cash equivalents | 32,357 | 80,042 | 22,222 | 67,935 | ||||||||||||||
| Cash and cash equivalents, beginning of period | 208,224 | 182,934 | 218,359 | 195,041 | ||||||||||||||
| Cash and cash equivalents, end of period | 240,581 | 262,976 | 240,581 | 262,976 |
See accompanying notes to the condensed consolidated interim financial statements.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
1.Description of business
SNDL Inc. ( SNDL or the Company ) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company's shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from Sundial Growers Inc. to SNDL Inc. .
The Company's head office is located at 101, 17220 Stony Plain Road, Edmonton, Alberta.
The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in certain Canadian jurisdictions where the private sale of adult-use cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis in Canada and for export pursuant to the Cannabis Act (Canada) (the Cannabis Act ), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult-use access in Canada.
SNDL and its subsidiaries operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. ( SunStream ) (note 13), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.
The Company's liquor retail operations are seasonal in nature. Accordingly, sales will vary by quarter based on consumer spending behaviour. The Company is able to adjust certain variable costs in response to seasonal revenue patterns; however, costs such as occupancy are fixed, causing the Company to report a higher level of earnings in the third and fourth quarters. This business seasonality results in quarterly performance that is not necessarily indicative of the year's performance. The cannabis industry is a growing industry and the Company has not observed significant seasonality as of yet.
The Company's common shares trade on the Nasdaq Capital Market under the ticker symbol SNDL and on the Canadian Securities Exchange under the symbol SNDL .
In early 2025, the U.S. administration imposed certain tariffs on imports from certain countries, including Canada, and in response, the Canadian administration imposed their own tariffs on certain imports from the United States. Canada and the United States continue ongoing negotiations on a new trade and security relationship, though the scope and terms of such negotiations and the agreements they may produce, if any, are unknown. These tariff announcements and the risk of further potential retaliatory tariffs have created uncertainty, which has permeated the economic and investment outlook, impacting current economic conditions, including such issues as the inflation rate and the global supply chain. Aside from the impact on the global economy, these tariffs may continue to impact SNDL.
SNDL is continuing to monitor the evolving situation and the impacts and potential consequences on its financial position. The Company did not experience a significant impact to its financial performance during the nine months ended September 30, 2025.
2.Basis of presentation
Statement of compliance
These condensed consolidated interim financial statements ( financial statements ) have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
annual consolidated financial statements for the year ended December 31, 2024. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2024.
Certain prior period amounts have been reclassified to conform to current year presentation. Specifically, changes to investments have been separated into additions to investments and principal payments from investments on the condensed consolidated interim statement of cash flows.
These financial statements were approved and authorized for issue by the board of directors of the Company (the Board ) on November 3, 2025.
3.Business acquisitions
On July 5, 2024, the Company announced that it had entered into a purchase agreement with Indiva Limited ( Indiva ) and its direct and indirect subsidiaries (collectively with Indiva, the Indiva Group ), pursuant to which the Company offered to purchase all of the issued and outstanding shares of Indiva and the business and assets of the Indiva Group (the Indiva Transaction ) for consideration comprising of a credit bid of all of the indebtedness of the Indiva Group owing to the Company, the retention of certain liabilities of the Indiva Group, and cash payments sufficient to repay certain priority indebtedness of the Indiva Group and costs associated with the Indiva Group's proceedings under the Companies' Creditors Arrangement Act (Canada).
On November 4, 2024, the Company announced that it had successfully closed the Indiva Transaction for consideration of approximately $21.1 million, comprised of the extinguishment of $20.7 million in total debt owing by Indiva to the Company and a cash payment of approximately $0.4 million.
The Company has engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed. The purchase price allocation is not final as the Company is continuing to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.
Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment. The fair value of consideration paid was as follows:
| Provisional | |||
| Extinguishment of term loan | 18,923 | ||
| Extinguishment of debtor-in-possession loan | 1,750 | ||
| Cash | 385 | ||
| 21,058 |
The preliminary fair value of the assets and liabilities acquired was as follows:
| Provisional | |||
| Cash | 3 | ||
| Accounts receivable | 4,057 | ||
| Inventory | 4,860 | ||
| Prepaid expenses and deposits | 205 | ||
| Right of use assets | 562 | ||
| Property, plant and equipment | 21,213 | ||
| Accounts payable and accrued liabilities | (4,100 | ) | |
| Lease liabilities | (286 | ) | |
| Total identifiable net assets acquired | 26,514 | ||
| Bargain purchase gain | (5,456 | ) | |
| 21,058 |
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
The excess of the aggregate fair value of the identifiable net assets acquired over the fair value of the consideration was $5.46 million, which was recorded as a bargain purchase gain included in other expenses, net, in the consolidated statements of loss and comprehensive loss for the year ended December 31, 2024. The bargain purchase gain was primarily due to the fair value adjustments on the identifiable property, plant and equipment and net working capital acquired.
As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, the accounting for the acquisition will be revised. All such adjustments will be recorded to the bargain purchase gain in the period that the adjustment is identified. For the three and nine months ended September 30, 2025, no changes were made to the preliminary fair value of the assets and liabilities acquired or the bargain purchase gain.
4.Segment information
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.
Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis products and accessories through corporate-owned and franchised retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as Corporate .
| Cannabis Retail | Cannabis Operations | Intersegment Eliminations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | |||||||||||||||||
| As at September 30, 2025 | ||||||||||||||||||||||||
| Total assets (1) | 211,092 | 207,865 | 418,957 | 322,158 | 410,830 | 166,116 | 1,318,061 | |||||||||||||||||
| Nine months ended September 30, 2025 | ||||||||||||||||||||||||
| Net revenue (2) | 246,960 | 107,544 | (51,391 | ) | 303,113 | 390,789 | 693,902 | |||||||||||||||||
| Gross profit | 63,974 | 23,452 | 87,426 | 100,993 | 188,419 | |||||||||||||||||||
| Operating income (loss) | 22,329 | (3,628 | ) | 18,701 | 24,276 | 1,775 | (62,852 | ) | (18,100 | ) | ||||||||||||||
| Earnings (loss) before income tax | 20,194 | (3,772 | ) | 16,422 | 21,356 | 1,775 | (64,694 | ) | (25,141 | ) | ||||||||||||||
| Three months ended September 30, 2025 | ||||||||||||||||||||||||
| Net revenue (2) | 85,021 | 37,389 | (17,579 | ) | 104,831 | 139,388 | 244,219 | |||||||||||||||||
| Gross profit | 22,465 | 5,008 | 27,473 | 36,704 | 64,177 | |||||||||||||||||||
| Operating income (loss) | 9,105 | (5,434 | ) | 3,671 | 11,222 | 1,543 | (27,486 | ) | (11,050 | ) | ||||||||||||||
| Earnings (loss) before income tax | 8,086 | (5,458 | ) | 2,628 | 10,374 | 1,543 | (27,864 | ) | (13,319 | ) |
(1)As at September 30, 2025, cash and cash equivalents have been allocated to Corporate from Investments.
(2)The Company has eliminated $51.4 million for the nine months ended September 30, 2025 and $17.6 million for the three months ended September 30, 2025 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
| Cannabis Retail | Cannabis Operations | Intersegment Eliminations | Cannabis Total | Liquor Retail | Investments (1) | Corporate | Total | |||||||||||||||||
| As at December 31, 2024 | ||||||||||||||||||||||||
| Total assets | 195,823 | 230,021 | 425,844 | 326,061 | 577,522 | 19,815 | 1,349,242 | |||||||||||||||||
| Nine months ended September 30, 2024 | ||||||||||||||||||||||||
| Net revenue (2) | 228,519 | 72,378 | (39,307 | ) | 261,590 | 401,179 | 662,769 | |||||||||||||||||
| Gross profit | 58,337 | 11,725 | 70,062 | 101,470 | 171,532 | |||||||||||||||||||
| Operating income (loss) | 7,255 | (1,728 | ) | 5,527 | 22,456 | 13,711 | (69,416 | ) | (27,722 | ) | ||||||||||||||
| Earnings (loss) before income tax | 4,637 | (2,133 | ) | 2,504 | 19,314 | 13,136 | (66,756 | ) | (31,802 | ) | ||||||||||||||
| Three months ended September 30, 2024 | ||||||||||||||||||||||||
| Net revenue (2) | 81,144 | 25,007 | (13,824 | ) | 92,327 | 144,565 | 236,892 | |||||||||||||||||
| Gross profit | 20,710 | 5,307 | 26,017 | 36,951 | 62,968 | |||||||||||||||||||
| Operating income (loss) | 4,395 | (703 | ) | 3,692 | 11,795 | (7,824 | ) | (26,174 | ) | (18,511 | ) | |||||||||||||
| Earnings (loss) before income tax | 3,328 | (65 | ) | 3,263 | 10,900 | (7,824 | ) | (24,241 | ) | (17,902 | ) |
(1)Total assets include cash and cash equivalents.
(2)The Company has eliminated $39.3 million for the nine months ended September 30, 2024 and $13.8 million for the three months ended September 30, 2024 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
Geographical disclosure
As at September 30, 2025, the Company had non-current assets related to credit investments in the United States of $391.1 million (December 31, 2024 $413.1 million). For the nine months ended September 30, 2025, share of profit of equity-accounted investees related to operations in the United States was a loss of $4.4 million (nine months ended September 30, 2024 profit of $1.0 million). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.
The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:
| As at | September 30, 2025 | December 31, 2024 | ||||
| Balance, beginning of year | 1,187 | 429 | ||||
| Increase in biological assets due to capitalized costs | 12,088 | 7,243 | ||||
| Net change in fair value of biological assets | 2,559 | (892 | ) | |||
| Transferred to inventory upon harvest | (12,327 | ) | (5,593 | ) | ||
| Balance, end of period | 3,507 | 1,187 |
Biological assets are valued in accordance with International Accounting Standard 41 Agriculture and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
The Company estimates the harvest yields for cannabis at various stages of growth. As at September 30, 2025, it is estimated that the Company's biological assets will yield approximately 13,795 kilograms (December 31, 2024 4,500 kilograms) of dry cannabis when harvested. During the nine months ended September 30, 2025, the Company harvested 19,681 kilograms of dry cannabis (nine months ended September 30, 2024 5,529 kilograms).
| As at | September 30, 2025 | December 31, 2024 | ||||
| Retail liquor | 74,907 | 73,538 | ||||
| Retail cannabis | 18,540 | 21,783 | ||||
| Harvested cannabis | ||||||
| Raw materials, packaging and components | 11,802 | 13,030 | ||||
| Work-in-progress | 15,237 | 16,058 | ||||
| Finished goods | 4,848 | 3,510 | ||||
| 125,334 | 127,919 |
During the three and nine months ended September 30, 2025, inventories of $177.7 million and $504.1 million were recognized in cost of sales as an expense (three and nine months ended September 30, 2024 $173.3 million and $488.4 million).
During the three and nine months ended September 30, 2025, the Company recognized inventory write downs of $1.8 million and $2.7 million (three and nine months ended September 30, 2024 $0.4 million and $3.4 million).
7.Assets held for sale
At September 30, 2025, assets held for sale were measured at their fair value less costs to sell and comprised of the following:
| As at | September 30, 2025 | December 31, 2024 | ||||
| Olds facility | 18,800 | |||||
| Extraction equipment | 746 | 251 | ||||
| 746 | 19,051 |
The Olds facility, located in Olds, Alberta, had a primary purpose to cultivate cannabis for the adult-use market. Upon closing the Olds facility, management committed to a plan to sell the Olds facility and classified the asset as available for sale. During the nine months ended September 30, 2025, management concluded that the Olds facility no longer met certain criteria for assets held for sale due to secondary commercial real estate market conditions in Alberta and therefore reclassified it back to property, plant and equipment.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
8.Right of use assets
| Cost | ||||
| Balance at December 31, 2024 | 217,251 | |||
| Additions | 9,331 | |||
| Renewals, remeasurements and dispositions | 20,315 | |||
| Balance at September 30, 2025 | 246,897 | |||
| Accumulated depreciation and impairment | ||||
| Balance at December 31, 2024 | 101,816 | |||
| Depreciation | 23,895 | |||
| Impairment reversal | (1,515 | ) | ||
| Balance at September 30, 2025 | 124,196 | |||
| Net book value | ||||
| Balance at December 31, 2024 | 115,435 | |||
| Balance at September 30, 2025 | 122,701 |
For the nine months ended September 30, 2025, the Company recorded the following net impairment reversals on right of use assets:
| Reporting Segment | |||||||||
| Three months ended | Liquor retail | Cannabis retail | Total | ||||||
| March 31, 2025 | (468 | ) | (468 | ) | |||||
| June 30, 2025 | (586 | ) | (586 | ) | |||||
| September 30, 2025 | (461 | ) | (461 | ) | |||||
| (1,515 | ) | (1,515 | ) |
Refer to note 9 for the significant assumptions applied in the impairment test.
For the nine months ended September 30, 2024, the Company recorded the following net impairment (reversals) losses on right of use assets:
| Reporting Segment | |||||||||
| Three months ended | Liquor retail | Cannabis retail | Total | ||||||
| March 31, 2024 | (159 | ) | 1,756 | 1,597 | |||||
| June 30, 2024 | (132 | ) | (283 | ) | (415 | ) | |||
| September 30, 2024 | (192 | ) | 98 | (94 | ) | ||||
| (483 | ) | 1,571 | 1,088 |
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
9.Property, plant and equipment
| Land | Production facilities | Leasehold improvements | Equipment | Construction in progress | Total | |||||||||||||
| Cost | ||||||||||||||||||
| Balance at December 31, 2024 | 9,454 | 51,251 | 78,250 | 108,903 | 2,571 | 250,429 | ||||||||||||
| Additions | 1,244 | 2,796 | 5,736 | 9,776 | ||||||||||||||
| Transfers from CIP | 2,571 | (2,571 | ) | |||||||||||||||
| Transfer from (to) assets held for sale | 18,800 | (507 | ) | 18,293 | ||||||||||||||
| Dispositions | (6 | ) | (2,285 | ) | (2,291 | ) | ||||||||||||
| Balance at September 30, 2025 | 9,454 | 70,051 | 82,059 | 108,907 | 5,736 | 276,207 | ||||||||||||
| Accumulated depreciation and impairment | ||||||||||||||||||
| Balance at December 31, 2024 | 4,960 | 38,126 | 61,533 | 104,619 | ||||||||||||||
| Depreciation | 1,254 | 6,700 | 8,158 | 16,112 | ||||||||||||||
| Impairment (recovery) | 689 | 4,943 | (862 | ) | (284 | ) | 4,486 | |||||||||||
| Dispositions | (6 | ) | (1,514 | ) | (1,520 | ) | ||||||||||||
| Balance at September 30, 2025 | 689 | 11,157 | 43,958 | 67,893 | 123,697 | |||||||||||||
| Net book value | ||||||||||||||||||
| Balance at December 31, 2024 | 9,454 | 46,291 | 40,124 | 47,370 | 2,571 | 145,810 | ||||||||||||
| Balance at September 30, 2025 | 8,765 | 58,894 | 38,101 | 41,014 | 5,736 | 152,510 |